Speaker List - 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference

7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference

9th-10th March 2023 | ILEC Conference Centre & Ibis London Earls Court, London
CONFERENCE SPEAKERS
Speakers
Øystein Rekdal
Øystein Rekdal
CEO,
Lytix Biopharma



Thomas Valerius
Thomas Valerius
Assistant Professor,
University of Kiel



Paul Parren
Paul Parren
EVP and Head of R&D,
Lava Therapeutics


Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. Prof. Parren obtained his PhD at the University of Amsterdam in 1992 after which he studied correlates of protection against viruses by human antibodies at Scripps Research in La Jolla, CA. From 2002-2017, he headed preclinical R&D at Genmab leading to the development of the approved therapeutic antibodies ofatumumab (Arzerra (2009), KESIMPTA (2020)), daratumumab (DARZALEX (2015)) and teprotumumab (Tepezza (2020)) and clinically translated technologies to generate bispecific and effector-function enhanced antibodies. He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center in Leiden and he leads Sparring Bioconsult, an independent biotech consulting company. Since 2018, he is EVP and head of R&D at Lava Therapeutics where he develops novel bispecific gamma-delta T-cell engagers for cancer therapy.


Senior Representative, Veracyte
Senior Representative, Veracyte
,



Anna Saal
Anna Saal
Senior Scientist,
Alligator Bioscience



Barbara Maurer
Barbara Maurer
Senior Scientist,
OncoOne



Victor Levitsky
Victor Levitsky
Chief Scientific Officer,
Targovax


Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his career as an academic research scientist, including Associate Professor positions at the Karolinska Institute in Sweden and the Johns Hopkins University School of Medicine in the USA. Before joining Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal Scientist with Roche in Zurich, and his most recent position has been VP, Head of Oncology Research at Molecular Partners, Zurich, Switzerland.


Samantha Bucktrout
Samantha Bucktrout
Vice President, Research Strategy,
PsiOxus Therapeutics



Ahuva Nissim
Ahuva Nissim
Professor, Antibody and Therapeutic Engineering,
Queen Mary University of London



Sari Pesonen
Sari Pesonen
Co-Founder, Head, R&D,
Valo Therapeutics


Sari Pesonen gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career at the University of Helsinki and was awarded a three-year post-doctoral research post by the Academy of Finland. Sari is a co-author in 60+ peer-reviewed research papers and inventor of patented adenovirus based cancer immunotherapy currently in multiple Ph2 clinical trials in the US and Europe. She has worked in biotech companies Oncos Therapeutics and Targovax in scientific lead positions before co-founding a Helsinki University spin out company Valo Therapeutics.


Ayse Meric Ovacik
Ayse Meric Ovacik
Senior Principal Scientist,
Genentech



John Bridgeman
John Bridgeman
Director of Cell Therapy Research,
Immetacyte Ltd


John undertook his PhD in 2004 under the supervision of Dr. David Gilham and Prof. Robert Hawkins at the University of Manchester. During this time his main interest was uncovering the signalling and molecular interactions of chimeric antigen receptors (CAR) and development of novel costimulatory CARs. In 2010 John moved to the labs of Prof. David Price and Prof. Andrew Sewell at Cardiff University where he focussed on T-cell receptor (TC         R) gene transfer, using it as a tool to understand biological phenomena such as alloreactivity and TCR cross-reactivity, as well as further developing adoptive cell therapy strategies. In 2013 he was awarded a Wellcome Trust/NISCHR ISSF research fellowship within the Institute of Infection and Immunity at Cardiff University studying cross-reactivity profiles of virus specific T-cells. John has been Director of Cell Therapy Research at Immetacyte (formally Cellular Therapeutics) since 2014


Senior Representative, BD Biosciences
Senior Representative, BD Biosciences
,



Sebastien Tabryun
Sebastien Tabryun
Chief Scientific Officer,
TransCure bioServices



Senior Representative, EpigenDx
Senior Representative, EpigenDx
,



Oliver Schon
Oliver Schon
VP, Product Development & CMC,
BiVictriX



Roberto De Luca
Roberto De Luca
Head, Antibody Therapeutics Research,
Philogen



Mark Throsby
Mark Throsby
Chief Scientific Officer,
Gadeta BV


Dr. Mark Throsby gained a PhD in Immunology from Monash University Melbourne, Australia and spent four years as a research fellow with CNRS in Paris. Dr Throsby started his industry career at the formation of Crucell NV and worked for 8 years there in various roles finally as Director of Antibody discovery. He joined Merus NV in 2008 as CSO and lead research at the company until 2020. Currently he is providing advice to entrepreneurs and operational support to life science companies. In that capacity he joined Gadeta in 2020 and is currently serving as COO/CSO. He sits on the board of ONA Therapeutics Srl and is Chairman of Alethiomics Ltd.


Fahima Kausar
Fahima Kausar
Team Lead,
Leucid Bio



Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy,
Kings College London, UK


Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK, specialising on antibody therapies for solid tumours. Her group has developed therapeutic antibody discovery to translation pathways, informed through dissecting B cells and the mechanisms of Th2 responses in cancer. Areas of research include deriving antibodies from human B cells, engineering antibodies of any specificity or class/isotype, and design of Fc-engineered antibodies and antibody-drug conjugates for cancer therapy. Her group is the first internationally to design, evaluate and translate anti-tumour IgE class antibodies to clinical testing. Sophia is a founder of IGEM Therapeutics Ltd, the first immuno-oncology company dedicated to developing IgE therapeutic agents for cancer. She serves as Secretary of the international AllergoOncology Task Force, a multidisciplinary consortium focused on the interface between allergies, IgE responses, and Th2 immunity, with cancer development since 2014.


Andrew Sewell
Andrew Sewell
Distinguished Research Professor and Wellcome Trust Senior Investigator,,
Cardiff University


Andrew Sewell is a Distinguished Research Professor and Wellcome Trust Senior Investigator, Cardiff University School of Medicine. His research aims to understand the basic biology of antigen recognition by human T-cells using novel pipelines for the discovery of new T-cell targets. Collaborations with various partners have been established to develop cancer immunotherapies and have resulted in recent co-authored papers in Nature Medicine with Immunocore, Adaptimmune and Autolus. Current research projects include: Dissection of successful immune responses after successful cancer immunotherapy or spontaneous remission; TCR gene transfer therapy (TCR-T); New CAR-T technologies; T-cell receptor-optimised peptide skewing or the repertoire of T-cells (TOPSORT); Artificial (non-biologic) T-cell antigens as vaccines; T-cell/TCR-based diagnostics in autoimmune disease; and, unconventional (non-HLA-restricted) T-cell responses to infection and tumours.